PROF Forecast



Bearish   ↔   Bullish



80% Confidence




Bullish Case: TULSA/Sonalleve commercial traction plus insider buying by the new president could compress PROF's extreme option IV and drive a sharp re-rate. The return surface retains a thin positive tail at longer holds, and M&A optionality on cheap medtech IP remains live. AI forecast nudges +1.65%; at $5.72, any procedure/installation or coverage win could produce >40% moves.




Bearish Case: Five-year return is -59.8%; the historical surface shows dense mass at negative-to-flat returns with persistent negative skew across holding windows. One-month drawdown of -16% with backwardated, illiquid options (453% IV on $2.50 puts) signals dilution, reimbursement, or financing event risk. Faded buyout hopes and management-communication complaints reinforce drift toward $5.




Potential Outcomes:
  1. 40% — Range $5.0–$6.5 for 3–6 months: surface mass near flat/negative returns, thin liquidity; falsified by break of $6.5 or $5.0 by Dec 31, 2026.
  2. 22% — Positive catalyst (coverage win, Tier-1 install, M&A chatter) → $7.5–$9 within 6–12 months; falsified if no material news by Mar 31, 2027.
  3. 22% — Dilution/financing or weak execution → $4.0–$5.0 within 3–6 months; falsified if non-dilutive funding announced by Dec 31, 2026.
  4. 10% — Runway/regulatory shock → below $4 within 6 months.
  5. 6% — Acquisition at premium (>50%) by end-2027.



September 30, 2026















See risk, trade-offs, and measured results before you decide.